Request Your Free White Paper Now:

"Beyond Geography: How FDA Really Assesses Multiregional Oncology Trials"

A former FDA Oncology Division leader breaks down what matters--and what doesn’t--when global data is used to support U.S. approval.

Global enrollment has become the backbone of modern oncology development, but regulators are sharpening their expectations. Geographic diversity alone is no longer enough. What FDA wants to know is whether your data truly represents U.S. patients and U.S. standards of care.

In this whitepaper, Dr. Harpreet Singh, Precision for Medicine Chief Medical Officer and former FDA Oncology Division Director, explains how regulators determine the relevance, credibility, and sufficiency of MRCT data, and the subtle factors that can make or break an application.

What You’ll Take Away

• How FDA evaluates whether multiregional data applies to U.S. patients
• The level of cross‑region consistency needed for regulatory confidence
• When single‑country or ex‑U.S.‑heavy datasets may be acceptable, and when they trigger requests for additional evidence

Get the whitepaper to see how FDA is applying these principles in real‑world reviews.

Offered Free by: Precision for Medicine
See All Resources from: Precision for Medicine